Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel

Executive Summary

Solithera's efficacy profile appears strong, but FDA has safety concerns, particularly its structural similarities to the controversial Ketek.


Related Content

Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks
Advisory Committee Recommendations Could Limit Use Of Solithera
Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV
Recent And Upcoming FDA Advisory Committees
Ketek Is Emerging As Lens For Wider Hill Scrutiny Of Clinical Trial Integrity


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts